Valuation: Incyte Corporation

Capitalization 20.85B 17.77B 16.47B 15.49B 28.83B 1,898B 30.92B 190B 75.09B 902B 78.19B 76.59B 3,293B P/E ratio 2025 *
17.1x
P/E ratio 2026 * 16x
Enterprise value 16.86B 14.37B 13.31B 12.52B 23.3B 1,534B 25B 154B 60.7B 730B 63.21B 61.92B 2,662B EV / Sales 2025 *
3.39x
EV / Sales 2026 * 2.77x
Free-Float
97.51%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-3.19%
1 week-0.58%
Current month+4.11%
1 month+2.10%
3 months+19.33%
6 months+52.60%
Current year+4.11%
More quotes
1 week 100
Extreme 100
108.58
1 month 97.63
Extreme 97.63
112.29
Current year 97.94
Extreme 97.94
112.29
1 year 53.56
Extreme 53.56
112.29
3 years 50.27
Extreme 50.27
112.29
5 years 50.27
Extreme 50.27
112.29
10 years 50.27
Extreme 50.27
153.15
More quotes
Manager TitleAgeSince
Chief Executive Officer 58 25/06/2025
Director of Finance/CFO 49 15/09/2025
President 62 04/06/2023
Director TitleAgeSince
Chairman 59 25/06/2025
Director/Board Member 72 19/01/2015
Director/Board Member 64 19/01/2015
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-3.04%-0.58%+39.96%+23.59% 20.85B
+0.25%-3.26%+6.74%+1.68% 75.21B
-0.05%+92.00%+92.00%+92.00% 60.39B
-0.58%+1.79%+40.49%+231.01% 57.05B
+0.11%+0.91%-35.76%-40.15% 57.13B
+0.32%-7.49%+17.00%-42.28% 24.12B
-2.52%-6.99%+164.55%+95.76% 18.99B
-3.02%+1.16%+56.42%+1,280.20% 18.01B
+2.34%+7.80%+18.95%-77.99% 16.34B
+0.47%-3.19%+112.28%+808.54% 14.7B
Average -0.60%+0.10%+51.26%+237.24% 36.28B
Weighted average by Cap. -0.37%-1.22%+37.69%+142.03%
See all sector performances

Financials

2025 *2026 *
Net sales 4.98B 4.24B 3.93B 3.7B 6.88B 453B 7.38B 45.37B 17.92B 215B 18.66B 18.28B 786B 5.53B 4.71B 4.37B 4.11B 7.64B 503B 8.2B 50.39B 19.91B 239B 20.73B 20.31B 873B
Net income 1.24B 1.06B 982M 923M 1.72B 113B 1.84B 11.33B 4.48B 53.79B 4.66B 4.57B 196B 1.33B 1.13B 1.05B 985M 1.83B 121B 1.97B 12.09B 4.78B 57.41B 4.98B 4.87B 210B
Net Debt -3.99B -3.4B -3.15B -2.97B -5.52B -364B -5.92B -36.41B -14.39B -173B -14.98B -14.67B -631B -5.56B -4.74B -4.39B -4.13B -7.68B -506B -8.24B -50.66B -20.02B -241B -20.84B -20.42B -878B
More financial data * Estimated data
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.3%); - royalties (13.7%); - income from research and cooperation agreements (1%).
Employees
2,617
More about the company
Date Price Change Volume
20/01/26 102.62 $ -3.38% 2,180,981
16/01/26 106.21 $ +0.92% 1,696,253
15/01/26 105.24 $ -0.67% 1,571,769
14/01/26 105.95 $ +2.44% 2,128,350
13/01/26 103.43 $ -2.73% 2,041,395

Delayed Quote Nasdaq, January 20, 2026 at 08:50 pm

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
106.21USD
Average target price
102.62USD
Spread / Average Target
-3.38%
Consensus

Quarterly revenue - Rate of surprise